|
|
CSL Behring Assurance
Because a Gap in Your Insurance Shouldn’t Mean a Gap in Treatment
The
CSL Behring Assurance Program is designed to ensure that people
who rely on eligible CSL Behring recombinant and plasma-derived therapies can
continue to receive these vital treatments even if they experience a lapse in
third-party, private health insurance.
Anyone who uses one of the following CSL Behring products and has
third-party, private health insurance can enroll in
CSL Behring Assurance:
- Factor therapies
Helixate® FS Antihemophilic
Factor (Recombinant)
Formulated with
Sucrose
Humate-P® Antihemophilic Factor/von Willebrand
Factor
Complex (Human), Dried, Pasteurized
Monoclate-P® Antihemophilic Factor (Human) Factor VIII:C
Pasteurized, Monoclonal Antibody
Purified
Mononine® Coagulation Factor IX (Human)
Monoclonal
Antibody Purified
- Immune globulin
therapies
Carimune® NF Nanofiltered Immune Globulin
Intravenous
(Human)
Warning: Immune Globulin Intravenous (Human) (IGIV) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. See boxed warning and the PRECAUTIONS and DOSAGE AND ADMINISTRATION section of
full Prescribing information for important information intended to reduce the risk of acute renal failure.
Vivaglobin® Immune Globulin Subcutaneous (Human)
- Alpha-1 therapy
Zemaira®
Alpha1-Proteinase
Inhibitor (Human)
CSL Behring Assurance allows you to build up a reserve of
complimentary product that you can easily access if you ever have a gap in your third-party, private health insurance coverage. It’s a protection plan that
costs you nothing and only requires that you complete a quick and easy
enrollment process to start gaining its benefits.
For more information about the CSL Behring Assurance Program, please visit
www.CSLBehringAssurance.com.
|